Klaricid Od

Clarithromycin, the active ingredient in Klaricid Od, is a macrolide antibiotic presented as an oral dosage form for systemic use. It treats a range of bacterial infections, including respiratory, skin and soft‑tissue, and certain gastrointestinal infections, in adult and pediatric patients where indicated.

GNH USA supplies Klaricid Od as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. This ensures reliable access to essential antimicrobial therapy across diverse healthcare settings.

Clarithromycin is employed to treat bacterial infections affecting the respiratory tract, skin, and certain gastrointestinal conditions.

- Community‑acquired bacterial pneumonia: reduces bacterial load and improves clinical outcomes. - Acute bacterial sinusitis: alleviates symptoms and eradicates causative pathogens. - Skin and soft‑tissue infections: resolves infection caused by susceptible organisms. - Helicobacter pylori eradication (in combination therapy): contributes to successful eradication regimens. - Acute exacerbations of chronic bronchitis: shortens duration of symptoms and prevents complications.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often reported. - Diarrhea: loose stools that may be self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste. - Vomiting: occasional emesis. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Liver enzyme elevation: signs of hepatic injury. - QT interval prolongation: risk of cardiac arrhythmias. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatotoxicity: rare cases of liver failure.

When prescribing clarithromycin, clinicians should consider several safety precautions to minimize risk. - Assess renal function: adjust use in patients with significant impairment. - Monitor liver enzymes: watch for hepatotoxicity during therapy. - Avoid use in patients with known QT prolongation: risk of cardiac arrhythmias. - Use caution in elderly: higher incidence of adverse effects. - Review concomitant medications: avoid strong CYP3A4 inhibitors. - Store at room temperature: keep in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Erythromycin: additive macrolide effects increase toxicity risk. - Ketoconazole: potent CYP3A4 inhibition can raise clarithromycin levels. - Ritonavir: strong CYP3A4 inhibitor leading to elevated plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: increased levels can cause toxicity; monitor concentrations. - Simvastatin: risk of increased statin exposure and myopathy; consider dose adjustment.